Novo Nordisk: completes acquisition of 3 sites for $11 billion

(CercleFinance.com) - Novo Nordisk has completed the acquisition of three manufacturing sites from Novo Holdings A/S.
This follows the completion of Novo Holdings' acquisition of Catalent, a global development and contract manufacturing organization based in New Jersey (USA).

The three manufacturing sites specialize in sterile drug filling and are located in Anagni (Italy), Brussels (Belgium) and Bloomington (Indiana, USA). The three sites employ over 3,000 people. Under the terms of the agreement, Novo Nordisk is acquiring the three manufacturing sites for an initial payment of 11 billion USD.

' The three sites will increase our large-scale, high-speed production capacity, while complementing our ongoing major expansions of our internal supply chain. This acquisition will enable us to reach a much larger number of people with serious chronic diseases', said Lars Fruergaard Jørgensen, President and CEO of Novo Nordisk.

Copyright (c) 2024 CercleFinance.com. All rights reserved.